Trial reportGastrointestinal endoscopy2011
Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus.
Trial report in Gastrointestinal endoscopy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-center Trial of Endoscopic Radiofrequency Ablation of Moderate and High-grade Intra-epithelial Squamous Neoplasia and Early Flat-type Squamous Cell Carcinoma Using the HALO Ablation System
Preemptive Radiofrequency Ablation for Esophageal Speckled Lugol Background Mucosa to Prevent Metachronous Neoplastic Recurrence After Complete Endoscopic Submucosal Dissection ~A Randomized Controlled Study
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.Updates in surgery · 2019Guideline
- Guideline
- Prospective study of endoscopic focal cryoballoon ablation for esophageal squamous cell neoplasia in China.Gastrointestinal endoscopy · 2019Trial
- Durability of radiofrequency ablation for treatment of esophageal squamous cell neoplasia: 5-year follow-up of a treated cohort in China.Gastrointestinal endoscopy · 2019Trial
- Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International Trial.Gastroenterology · 2015Trial
- Trial
- Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran.British journal of cancer · 2014Trial
- Radiofrequency Ablation as an Alternative and Novel Procedure in the Intraepithelial Neoplasia Management: A Systematic Scoping Review.Health science reports · 2025Review
- Long-term Outcomes of Endoscopic Radiofrequency Ablation versus Endoscopic Submucosal Dissection for Widespread Superficial Esophageal Squamous Cell Neoplasia.Gut and liver · 2025Article
- Atrial Flutter After Radiofrequency Ablation for Barrett's Esophagus: A Case Report.The American journal of case reports · 2023Article
- Comparison between ESD and RFA in patients with total or near-total circumferential early esophageal squamous cell neoplasia.Surgical endoscopy · 2023Article
- Article
- Combination of Endoscopic Resection and Radiofrequency Ablation for the Treatment of Esophageal Squamous Cell Neoplasia With Multiple Lugol-Voiding Lesions.Frontiers in oncology · 2021Article
- Methylated DNA Markers of Esophageal Squamous Cancer and Dysplasia: An International Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Radiofrequency Ablation for Early Superficial Flat Esophageal Squamous Cell Neoplasia: A Comprehensive Review.Gastroenterology research and practice · 2020Review
- Endoscopic management of esophageal cancer.World journal of gastrointestinal oncology · 2019Review
- Endoscopic resection for early esophageal carcinoma.Journal of thoracic disease · 2019Review
- Early detection and therapeutics.Molecular oncology · 2019Review
- Role of endoscopic therapy in early esophageal cancer.World journal of gastroenterology · 2018Article
- Endoscopic Treatment of Early-Stage Esophageal Cancer.Current oncology reports · 2018Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundRadiofrequency ablation (RFA) is safe and effective for eradicating neoplasia in Barrett's esophagus.
objectiveTo evaluate RFA for eradicating early esophageal squamous cell neoplasia (ESCN) defined as moderate-grade squamous intraepithelial neoplasia (MGIN) and high-grade squamous intraepithelial neoplasia (HGIN) and early flat-type esophageal squamous cell carcinoma (ESCC).
designProspective cohort study.
settingTertiary referral center. PATIENTS: Esophageal unstained lesions (USLs) were identified using Lugol's chromoendoscopy. Inclusion criteria were at least 1 flat (type 0-IIb) USL 3 cm or larger, USL-bearing esophagus 12 cm or less, and a consensus diagnosis of MGIN, HGIN, or ESCC by 2 expert GI pathologists. Exclusion criteria were previous endoscopic resection or ablation, stricture, or any nonflat mucosa.
interventionsCircumferential RFA creating a continuous treatment area (TA) including all USLs. At 3-month intervals thereafter, chromoendoscopy with biopsies followed by focal RFA of USLs, if present. MAIN OUTCOME MEASUREMENTS: Complete response (CR) at 12 months defined as absence of MGIN, HGIN, or ESCC in the TA, CR after 1 RFA session, neoplastic progression from baseline, and adverse events.
resultsTwenty-nine patients (14 male, mean age 60.3 years) with MGIN (n = 18), HGIN (n = 10), or ESCC (n = 1) participated. Mean USL length was 6.2 cm (TA 8.2 cm). At 3 months after 1 RFA session, 86% of patients (25/29) had a CR. At 12 months, 97% of patients (28/29) had a CR. There was no neoplastic progression. There were 4 strictures, all dilated to resolution. LIMITATIONS: Single-center study with limited number of patients.
conclusionsIn patients with early ESCN (MGIN, HGIN, flat-type ESCC), RFA was associated with a high rate of histological complete response (97% of patients), no neoplastic progression, and an acceptable adverse event profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.